20/20 Biolabs Inc.
20/20 Biolabs Inc.
- Market cap
- $2.20M
Your view on AIDX
Overview
What the company does, where it operates, and who runs it.
About 20/20 Biolabs Inc.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Jonathan Cohen
- Headquarters
- 15810 Gaither Road, Gaithersburg, MD, US
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Jonathan Cohen
- Headquarters
- 15810 Gaither Road, Gaithersburg, MD, US
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test.
It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market.
The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for 20/20 Biolabs Inc.. Starting points for 20/20 Biolabs Inc.: EPS -$0.49, beta 1.54 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for 20/20 Biolabs Inc.. Trailing twelve-month EPS for 20/20 Biolabs Inc. stands at -$0.49. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Targets, low to high
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.07 | $0.00 | −$0.52 | −$0.38 |
| Lowest estimate | −$0.07 | $0.00 | −$0.52 | −$0.38 |
| Highest estimate | −$0.07 | $0.00 | −$0.52 | −$0.38 |
| Number of analysts | 1 | 0 | 1 | 1 |
| A year ago | — | −$0.281 | — | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $896000.00 | $1.33M | $2.62M | $5.77M |
| Lowest estimate | $896000.00 | $1.33M | $2.62M | $5.77M |
| Highest estimate | $896000.00 | $1.33M | $2.62M | $5.77M |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | $353375.00 | — | — |
| Growth vs a year ago | — | +275.8% | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for 20/20 Biolabs Inc.. 20/20 Biolabs Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| THCTenet Healthcare Corporation | Healthcare | NYSE | $20.9B | ||
| TTALFTerveystalo Oyj | Healthcare | OTC | $1.6B | ||
| UHSUniversal Health Services, Inc. | Healthcare | NYSE | $9.0B | ||
| UNHLFEC Healthcare | Healthcare | OTC | $101.9M | ||
| UNVCUnivec, Inc. | Healthcare | OTC | $6.3M | ||
| UPDCUPD Holding Corp. | Healthcare | OTC | $38,996 | ||
| USPHU.S. Physical Therapy, Inc. | Healthcare | NYSE | $1.4B | ||
| VLXCVeltex Corporation | Healthcare | OTC | $3.9M | ||
| VMDViemed Healthcare, Inc. | Healthcare | NASDAQ | $322.8M | ||
| WELL.TOWELL Health Technologies Corp. | Healthcare | TSX | $867.7M | ||
| WEQLWellQuest Medical & Wellness Corporation | Healthcare | OTC | $7,212 | ||
| WHTCFWELL Health Technologies Corp. | Healthcare | OTC | $735.5M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in AIDX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold 20/20 Biolabs Inc., and how their positions are changing. At a $2.2M market value, institutional positions materially move 20/20 Biolabs Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by 20/20 Biolabs Inc. executives and directors. Shares of 20/20 Biolabs Inc. have traded between $0.40 and $50.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for 20/20 Biolabs Inc.. Coverage tracks 20/20 Biolabs Inc. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of 20/20 Biolabs Inc.